Abacavir EP Impurity C (Abacavir Related Compound A) with high purity >98% in stock CAS 124752-25-6 CAS NO.124752-25-6

Topbatt Chemical Co. Ltd., Established in 2019, located in Shenzhen, Guangdong Province, is a Manufacturer and Trading company which specialized in fine chemicals like Pharmaceutical Reference Standards and Stable Isotopes. Our Stable Isotopes product line including 2H Labelled APIs, Reagents and Intermediates, 13C Labelled Substance, 15N Labelled Substance and 18O Labelled Substance.

We own a number of Senior pharmaceutical synthetic engineer, analysis engineer and analytical testing instrument. It make us have more than 1700 varieties compouds with high purity in stock in a short time.

We can provide you not only stock items, but also Custom Synthesis Service.

All of our products provided with COA, HPLC/GC, HNMR, qNMR, MS Spectrum.

After-sales issues will be settled in 24 hours.

Product Name: Abacavir EP Impurity C(Abacavir Related Compound A)

Chemical Name: ((1S,4R)-4-(2,6-diamino-9H-purin-9-yl)cyclopent-2-enyl)methanol

Molecular Formula: C11H14N6O

Molecular Weight: 246.27

CAS#: 124752-25-6

Purity: >98%

Appearence: Off-White to Pale Yellow Solid

Price: Negotiable

Available Document: COA, HPLC/GC, HNMR, qNMR, MS Spectrum

Payment Term: Payment in advance by T/T.

Shipment: Package will dispatched in 7-15 days(According to the date of payment) by air.

Trade Term: EXW, FOB, CFR, DDU, DDP, ect.

((1S,4R)-4-(2,6-diamino-9H-purin-9-yl)cyclopent-2-enyl)methanol, Descyclopropyl Abacavir (Abacavir EP Impurity C; Abacavir Related Compound A) is an intermediate of Abacavir. Abacavir is a carbocyclic 2'-deoxyguanosine nucleoside reverse transcriptase inhibitor and an anti-HIV drug used to treat HIV infection (1). Intracellular enzymes convert Abacavir to its active form, carbovir-triphosphate (CBV-TP), which then selectively inhibits HIV reverse transcriptase by incorporating into viral DNA (2). Abacavir is metabolized in the liver by uridine diphosphate glucuronyltransferase and alcohol dehydrogenase resulting in inactive glucuronide and carboxylate metabolites, respectively.

Reference: 

(1) Jackson, A., et al.: Antivir Ther. 17, 19 (2012)

(2) Yuen, G. J., et al.: Clin Pharmacokinet. 47, 351 (2008)